Latest Europe News

Vection Technologies reported a 9.6% revenue increase to $36 million and a 25.3% reduction in net loss for FY2025, driven by operational improvements and a key acquisition.

Scalare Partners reports a 26% rise in FY25 revenue, driven by strong service demand and key acquisitions, including Inhouse Ventures and the pending Tank Stream Labs deal.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Clean TeQ Water Limited reported a reduced loss of $2.8 million for FY25 and increased its stake in Go2Lithium Inc to 60%, marking a strategic shift as it advances water treatment and critical metals recovery projects worldwide.

BlinkLab Limited reported a substantial net loss of $5.7 million for FY2025, driven by intensive R&D and clinical trial activities, while securing $7.66 million in fresh capital to fuel its smartphone-based neurodevelopmental diagnostic platform targeting autism and ADHD.

CPT Global Limited reported a 12% revenue increase to $23.1 million for FY2025, driven by growth in the Northern Hemisphere segment, while narrowing its net loss to $706,214. The company is strategically pivoting towards larger markets and investing in technology and talent to fuel future growth.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

Salter Brothers Emerging Companies Limited posted a 25.5% decline in profit after tax for FY25 but marked a milestone with its inaugural dividend payment. The fund remains confident in its small-cap investment strategy amid easing interest rates and geopolitical volatility.

Camplify Holdings Limited reported a 12.3% revenue decline to $42.1 million and a near doubling of net loss to $15.8 million in FY25, reflecting a year of strategic transformation including the launch of its MyWay protection product and completion of European platform integration.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

RAS Technology Holdings Limited reported a robust 31% increase in revenue to A$21.3 million for FY25, alongside its first net profit after tax since listing, driven by strategic acquisitions and global expansion.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.